While Philips reported a decrease in overall sales, the adjusted EPS increased and sales growth was positive when excluding the impact of the Respironics consent decree provisions. This suggests that the core business segments are performing well, which could mitigate negative investor sentiment regarding the sales decline. However, the presence of the one-time provision and the overall sales decline may temper any potential positive stock movement, leading to a neutral short-term impact.